Ningbo Menovo Pharmaceutical's subsidiary has obtained the registration certificate for Irbesartan Hydrochlorothiazide Tablets.

Ningbo Menovo Pharmaceutical (603538.SH) announced that its wholly-owned subsidiary, Ningbo Menovo Pharmaceutical Tiankang Pharmaceutical Co., Ltd. ("Ningbo Menovo Pharmaceutical Tiankang"), recently received the "Drug Registration Certificate" issued by the National Medical Products Administration. Indication: Used for the treatment of primary hypertension. The compound contains the angiotensin II receptor antagonist eprosartan and the thiazide diuretic hydrochlorothiazide. The combination of hydrochlorothiazide and eprosartan within its recommended therapeutic dose range can produce a synergistic antihypertensive effect.